Sign in
Taking people in AustriaNo phase

Registry following adults with advanced colorectal cancer after two prior treatments

Records treatments and outcomes in adults with spread colorectal cancer after two prior therapies.

Key facts

Who runs it
Arbeitsgemeinschaft medikamentoese Tumortherapie
Where
Linz, Rankweil, Salzburg, Steyr, Wels, and Zams, AustriaSee the 7 sites
Trial code
Registry title
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Status
Recruiting
People taking part
500 people, planned
Started
31 Oct 2024
Expected to end
Dec 2034
Type of study
Observational
Record updated
10 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry is looking for adults with metastatic colorectal cancer, confirmed by a tissue sample, who have already had at least two lines of treatment for advanced disease.

Age
18 years or older
Sex
All sexes can join
Disease stage
Metastatic colorectal cancer (mCRC), diagnosed from tissue
Earlier treatment
At least 2 earlier lines of palliative systemic therapy, including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (if RAS/BRAF wildtype) and anti-PD1 therapy (if MSI/MMRd). People who had mFOLFOXIRI with or without anti-VEGF or anti-EGFR as first treatment, or who cannot receive 5-FU, oxaliplatin or irinotecan, can join after first-line treatment.

Main reasons for not taking part

  • No specific exclusion criteria, because this registry is non-interventional

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • patients ≥ 18 years with tissue-based diagnosis of mCRC
  • ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.)

Who cannot take part

  • Due to the non-interventional design of this registry, there are no specific exclusion criteria

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

The criteria questions were written by an AI system from the criteria published for NCT06678919. Checked by software, not by a doctor.

  • How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?

This trial is currently available in Austria.

  • KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische OnkologieLinz, AustriaContact: Clemens Schmitt, MD (principal investigator)Taking people
  • Ordensklinikum Linz, BHS - Interne ILinz, AustriaContact: Holger Rumpold, MD (principal investigator)Taking people
  • LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)Rankweil, AustriaContact: Thomas Winder, MD (principal investigator)Taking people
  • Department of Internal Medicine III, Paracelsus Medical University SalzburgSalzburg, AustriaContact: Florian Huemer, Priv.Doz. DrTaking people
  • Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, AngiologieSteyr, AustriaContact: Georg Schreil, MD (principal investigator)Taking people
  • Klinikum Wels: Abteilung für Innere Medizin IVWels, AustriaContact: Sonja Heibl, MD (principal investigator)Taking people
  • KH Zams: Innere Medizin Internistische Onkologie und HämatologieZams, AustriaContact: Ewald Wöll, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Plain-language title
Registry following adults with advanced colorectal cancer after two prior treatmentsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT06678919, who can take part
Publications
Record updated
10 April 2025